Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Terns Pharmaceuticals Inc. currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 5 actions are distributed across 3 distinct art units, suggesting a range of pharmaceutical inventions are under review. The prosecution involves 5 distinct examiners, which means that every pending case is being handled by a different individual.
SEITZ, ANTHONY JOSEPH is the busiest examiner for this portfolio, currently overseeing 1 pending office action. This count of 1 is the highest number of actions assigned to any single examiner in the group. With 5 distinct examiners for 5 pending office actions, the workload is perfectly distributed, as no examiner is managing more than one case. The 3 distinct art units involved mean that the 5 pending office actions are subject to the standards of several different examination groups. Practitioners should note that they will be dealing with 5 different examiners, which may lead to a variety of prosecution experiences. Since the busiest examiner, SEITZ, ANTHONY JOSEPH, only has 1 pending office action, there is no single primary contact for the company's active Biotechnology & Pharmaceuticals portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEITZ, ANTHONY JOSEPH | 1 | 68.3% | +27.0% |
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
| JAIN, AVEESH | 1 | — | — |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.5% | +23.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548650 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | WHITE, DAWANNA SHAR-DAY | 26d |
| 18956385 | COMPOUNDS AS GLP-1R AGONISTS | SEITZ, ANTHONY JOSEPH | — |
| 18622057 | COMPOUNDS AS GLP-1R AGONISTS | ROZOF, TIMOTHY R | — |
| Art Unit | Apps |
|---|---|
| 4100 | 1 |
| 1625 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18956385 | COMPOUNDS AS GLP-1R AGONISTS | SEITZ, ANTHONY JOSEPH | — | DP | Non-Final OA | — | Pending | Nov 22, 2024 |
| 18651843 | TREATMENT OF LIVER DISORDERS WITH A THR-ß AGONIST | YOO, SUN JAE | — | §103 | Non-Final OA | — | Pending | May 01, 2024 |
| 18629151 | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF | JAIN, AVEESH | 4100 | §103Other | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18622057 | COMPOUNDS AS GLP-1R AGONISTS | ROZOF, TIMOTHY R | 1625 | §102DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18548650 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | WHITE, DAWANNA SHAR-DAY | 1627 | DP | Final Rejection | 26d | Pending | Sep 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial